Neos Therapeutics, Inc.
Funding rounds
6 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2014 | $21 M | No. 6 | $10 to $50 million | equity, options | SEC | |
| Mar 2014 | $3 M | No. 5 | $2 to $10 million | equity | SEC | |
| Dec 2013 | $16 M | No. 4 | $10 to $50 million | equity | SEC | |
| Jul 2012 | $18 M | No. 3 | $10 to $50 million | equity | SEC | |
| May 2011 | $14 M | No. 2 | $10 to $50 million | equity | SEC | |
| Jun 2009 | $24 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Neos Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2015).
SEC Form D · Feb 2015
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Feb 2015
That is all the official record says: Neos Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
23 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Alan L. Heller | Person | not stated | not stated | Held Series B, B-1 and C preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Burrill Life Scienes Capital Fund III L.P. | Fund or asset manager | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| CMEA Ventures VII LP | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Cmea Ventures VII (parallel) LP | Venture capital | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Delaware Street Capital L.P. | Fund or asset manager | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Delaware Street Capital Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Dorothy Engelking | Person | not stated | not stated | Held Series C preferred stock (Form 3, 2015) | SEC Form 3 |
| DSC Advisors, L.L.C. | Fund or asset manager | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| DSC Advisors, L.P. | Fund or asset manager | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| DSC Managers, L.L.C. | Other | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Essex Capital Corp | Fund or asset manager | not stated | not stated | Held Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Gregory J. Robitaille | Person | not stated | not stated | Held Series B, B-1 and C preferred stock, director (Form 3, 2015) | SEC Form 3 |
| Jack W. Schuler | Person | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Kearny Venture Assoicates II LLC | Venture capital | not stated | not stated | Held Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Mark Tengler | Person | not stated | not stated | Held Series C preferred stock (Form 3, 2015) | SEC Form 3 |
| Presidio Partners 2007 GP, LLC | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Presidio Partners 2007 GP, L.P. | Fund or asset manager | not stated | not stated | Held Series B and C preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Vipin K. Garg | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2015) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 57 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Arlen Ewart | Controller | Feb 2015 |
| Asif Mughal | VP Quality Assurance | Feb 2015 |
| Carolyn Sikes | VP Clinical Affairs | Feb 2015 |
| Dorothy Engelking | VP Regulatory Affairs | Feb 2015 |
| Margaret Cabano | VP Operations | Feb 2015 |
| Mark Tengler | Chief Technology Officer | Feb 2015 |
| Richard Eisenstadt | Chief Financial Officer and Secretary | Feb 2015 |
| Russ McMahen | VP Research and Development | Feb 2015 |
| Stacie Switzer | Assistant Secretary | Feb 2015 |
| Steven Lutz | VP Sales | Feb 2015 |
| Vipin Garg | President and Chief Executive Officer | Feb 2015 |
| Victor Miller | VP Finance | Apr 2014 |
| Ellen Hoffing | Co-President and Chief Operating Officer | Mar 2014 |
| Bryan Hill | Executive officer | Jul 2012 |
| Mark Van Ausdal | Executive officer | Jul 2012 |
| Dorothy Frank | Executive officer | Jun 2011 |
| Margaret Lokash | Executive officer | Jun 2011 |
| John Clark | Executive officer | Nov 2009 |
| Alan Heller | Chairman | Feb 2015 |
| Bryant Fong | Director | Feb 2015 |
| Edward Schnipper | Director | Feb 2015 |
| Greg Robitaille | Director | Feb 2015 |
| Ralph Iannelli | Director | Feb 2015 |
| Vipin Garg | President and Chief Executive Officer | Feb 2015 |
| Christopher Clement | Director | Jul 2012 |
| Karl Handelsman | Director | Jul 2012 |
| Chris Clement | Director | Nov 2009 |